Healthcare / BiotechnologyNasdaqCM
$2.13
+0.24 (+12.70%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 21%
FCF escenarios
weak_data · normalized FCF $-6.1M · quality 52.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
29/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$6M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-93.2%
↓Gross Margin
N/A
•Debt/Equity
0.10
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2021–2025 · 4 años de histórico normalizado
Revenue CAGR
+101.4%
FCF CAGR
—
FCF margin
-41458.0%
FCF / Net income
0.95x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $14825.0 · net income $-6.5M · FCF $-6.1M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | $14825.00 | $14825.00 | $34890.00 | $17065.00 | $950.00 | $901.00 |
| Net Income | $-6.5M | $-6.5M | $-8.4M | $-8.4M | $-4.7M | $-620448.00 |
| EBITDA | $-6.1M | $-6.1M | $-8.1M | $-1.5M | $-4.6M | $-604448.00 |
| EPS | -3.71 | -3.71 | -9.35 | -19.80 | -45.30 | -15.90 |
| Operating Margin | -43737.5% | -43737.5% | -23977.9% | -42440.4% | -478784.3% | -68862.2% |
| Net Margin | -43832.5% | -43832.5% | -24028.2% | -49087.8% | -490630.0% | -68862.2% |
| Balance Sheet | ||||||
| Debt/Equity | 0.10 | 0.10 | 0.10 | 0.43 | 0.20 | — |
| Current Ratio | 15.76 | 15.76 | — | — | — | — |
| Cash Flow | ||||||
| Free Cash Flow | $-6.1M | $-6.1M | $-5.4M | $-6.5M | $-5.2M | — |
| Returns | ||||||
| ROE | -93.2% | -93.2% | -87.7% | -283.2% | -108.4% | -58.1% |
| Valuation | ||||||
| P/B | 0.53 | 0.53 | 2.69 | 9.86 | 0.78 | — |
| Growth & Yield | ||||||
| Revenue Growth | -57.5% | -57.5% | 104.5% | 1696.3% | — | — |
| EPS Growth | 60.3% | 60.3% | 52.8% | 56.3% | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-46.6%
Start / end P/E
n/dx → n/dx
EPS bridge
-9.35 → -3.71
Residual
-46.6%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.